Knee Osteoarthritis
Conditions
Interventions
experimental group:Diclofenac sodium sustained-release tablet 50mg orally, twice a day
Ultra-short wave therapy
Shexiang Chufeng pain Relief cream for external use
control group:Diclofenac sodium sustained-release tablet 50mg orally, twice a day
Ultra-short wave therapy
Sponsors
Jiangsu Shengze Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Meet the Western medical diagnostic criteria for knee osteoarthritis in the Guidelines for Diagnosis and Treatment of Osteoarthritis (2021 edition); 2. Pain VAS scores of 3.0 to 7.4 (including 3.0 and 7.4); 3. The subjects give informed consent, voluntarily participate in the experiment and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergy, rubber allergy or known allergy to the ingredients of this product; 2. Severe cardiovascular or peripheral vascular diseases, abnormal liver and kidney function (AST, ALT > 1.5 times the upper limit of normal, blood creatinine > the upper limit of normal), bleeding diseases, coagulation dysfunction, etc.; 3. The knee joint has a serious organic injury or has undergone surgery; 4. Local skin rupture, skin damage or infection and scar skin in the knee joint; 5. Pregnant and lactating women; Or have a birth plan during the study period; 6. Any other circumstances that, in the opinion of the investigator, endanger the safety of the subject, affect the evaluation of the investigator, or have poor adherence to the protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS; | — |
Secondary
| Measure | Time frame |
|---|---|
| Western Ontario and McMaster Universities Osteoarthritis Index;adverse reaction; | — |
Countries
China
Contacts
Public ContactHe Chuan
Jiangsu Shengze Hospital
Outcome results
None listed